CORT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 20.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $7,991,445.07

Corcept Therapeutics Insider Trading History Chart

Corcept Therapeutics Share Price & Price History

^$54.31

▲ +1.69 (3.21%)

As of 11/19/2024 01:00 AM ET

Days: 30 | 90 | 365

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Corcept Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/11/2024	Daniel N. Swisher, Jr.	Director	Sell	2,200	$59.88	$131,736.00
11/4/2024	William Guyer	Insider	Sell	3,394	$48.97	$166,204.18	5,796
11/1/2024	William Guyer	Insider	Sell	6,606	$48.97	$323,495.82	5,796
10/1/2024	Gary Charles Robb	Insider	Sell	11,000	$46.28	$509,080.00	22,772
9/3/2024	William Guyer	Insider	Sell	10,000	$35.30	$353,000.00	6,039
8/26/2024	Gary Charles Robb	Insider	Sell	3,101	$35.71	$110,736.71	23,190
8/1/2024	Daniel N. Swisher, Jr.	Director	Sell	150	$38.50	$5,775.00
8/1/2024	William Guyer	Insider	Sell	10,000	$38.67	$386,700.00	6,039
7/1/2024	Daniel N. Swisher, Jr.	Director	Sell	2,200	$32.81	$72,182.00
7/1/2024	Joseph Douglas Lyon	Insider	Sell	5,000	$32.49	$162,450.00	9,290
6/3/2024	Daniel N. Swisher, Jr.	Director	Sell	2,200	$30.21	$66,462.00
6/3/2024	Joseph Douglas Lyon	Insider	Sell	5,000	$30.18	$150,900.00	7,314
5/28/2024	Gary Charles Robb	Insider	Sell	11,000	$30.39	$334,290.00	20,203
5/13/2024	Sean Maduck	Insider	Sell	50,000	$28.00	$1,400,000.00	85,222
5/9/2024	Joseph Douglas Lyon	Insider	Sell	7,227	$26.00	$187,902.00	7,314
5/2/2024	Joseph Douglas Lyon	Insider	Sell	10,830	$26.00	$281,580.00	7,314
4/4/2024	Joseph Douglas Lyon	Insider	Sell	5,443	$26.00	$141,518.00	7,314
4/1/2024	Daniel N. Swisher, Jr.	Director	Sell	2,200	$25.30	$55,660.00
4/1/2024	Joseph Douglas Lyon	Insider	Sell	500	$26.01	$13,005.00	7,314
3/27/2024	Sean Maduck	Insider	Sell	25,953	$25.01	$649,084.53	85,222
3/18/2024	Sean Maduck	Insider	Sell	17,219	$25.00	$430,475.00	75,222
3/1/2024	Daniel N. Swisher, Jr.	Director	Sell	2,200	$23.59	$51,898.00
2/16/2024	Joseph Douglas Lyon	CAO	Sell	1,000	$26.00	$26,000.00	6,774
2/16/2024	Sean Maduck	Insider	Sell	27,068	$25.97	$702,955.96	74,455
2/1/2024	Daniel N. Swisher, Jr.	Director	Sell	2,200	$22.00	$48,400.00
1/2/2024	Daniel N. Swisher, Jr.	Director	Sell	2,200	$22.11	$48,642.00
12/22/2023	William Guyer	Insider	Sell	10,000	$32.00	$320,000.00	6,643
12/5/2023	Gary Charles Robb	Insider	Sell	1,381	$26.27	$36,278.87	27,602
12/4/2023	Joseph Douglas Lyon	CAO	Sell	2,432	$26.00	$63,232.00	5,854
12/1/2023	Daniel N. Swisher, Jr.	Director	Sell	2,200	$25.47	$56,034.00
12/1/2023	Joseph Douglas Lyon	CAO	Sell	2,568	$26.00	$66,768.00	5,854
12/1/2023	Sean Maduck	Insider	Sell	25,000	$25.56	$639,000.00	73,291
11/2/2023	Joseph Douglas Lyon	CAO	Sell	3,977	$28.11	$111,793.47	5,854
11/1/2023	Daniel N. Swisher, Jr.	Director	Sell	2,200	$27.96	$61,512.00
11/1/2023	Sean Maduck	Insider	Sell	5,112	$28.08	$143,544.96	73,291
10/10/2023	Sean Maduck	Insider	Sell	18,471	$27.29	$504,073.59	73,291
10/6/2023	Joseph Douglas Lyon	CAO	Sell	2,582	$27.24	$70,333.68	5,854
10/6/2023	Sean Maduck	Insider	Sell	3,498	$27.24	$95,285.52	73,610
10/2/2023	Daniel N. Swisher, Jr.	Director	Sell	2,200	$27.32	$60,104.00
10/2/2023	Joseph Douglas Lyon	CAO	Sell	2,418	$27.25	$65,890.50	5,854
10/2/2023	Sean Maduck	Insider	Sell	3,031	$27.24	$82,564.44	73,610
9/19/2023	Sean Maduck	Insider	Sell	25,000	$32.48	$812,000.00	73,610
9/5/2023	Daniel N. Swisher, Jr.	Director	Sell	2,200	$32.90	$72,380.00
9/1/2023	Daniel N. Swisher, Jr.	Director	Sell	1,550	$32.73	$50,731.50
9/1/2023	Joseph Douglas Lyon	CAO	Sell	5,000	$32.73	$163,650.00	5,132
8/21/2023	Joseph Douglas Lyon	CAO	Sell	4,588	$31.19	$143,099.72	5,132
8/14/2023	David L. Mahoney	Director	Sell	25,000	$30.95	$773,750.00	11,297
8/14/2023	Hazel Hunt	Insider	Sell	20,455	$30.89	$631,854.95	73,146
8/7/2023	Daniel N. Swisher, Jr.	Director	Sell	2,850	$30.14	$85,899.00
8/7/2023	Joseph Douglas Lyon	CAO	Sell	412	$31.22	$12,862.64	4,720
6/6/2023	Joseph Douglas Lyon	CAO	Sell	10,000	$23.60	$236,000.00	5,132
5/9/2023	Gary Charles Robb	Insider	Sell	30,000	$23.87	$716,100.00	33,997
12/1/2022	Sean Maduck	Insider	Sell	625	$25.28	$15,800.00	56,462
11/22/2022	Gary Charles Robb	Insider	Sell	4,814	$26.03	$125,308.42	21,329
11/17/2022	Gary Charles Robb	Insider	Sell	10,000	$26.06	$260,600.00	39,544
11/10/2022	Sean Maduck	Insider	Sell	25,000	$25.57	$639,250.00	56,462
10/3/2022	Sean Maduck	Insider	Sell	25,000	$25.64	$641,000.00	56,462
9/7/2022	Gary Charles Robb	Insider	Sell	50,000	$26.06	$1,303,000.00	49,544
8/9/2022	Sean Maduck	Insider	Sell	200	$28.70	$5,740.00	40,024
7/18/2022	Sean Maduck	Insider	Sell	25,000	$27.37	$684,250.00	40,024
7/6/2022	Gary Charles Robb	Insider	Sell	45,000	$26.00	$1,170,000.00	24,123
7/6/2022	Joseph K. Belanoff	CEO	Sell	279,908	$26.27	$7,353,183.16	2,538,218
5/19/2022	Gary Charles Robb	Insider	Sell	6,127	$19.57	$119,905.39	36,446
5/17/2022	Gary Charles Robb	Insider	Sell	28,745	$19.55	$561,964.75	42,701
3/17/2022	Gary Charles Robb	Insider	Sell	7,512	$24.68	$185,396.16

This company will win the AI race

From Porter & Company | Ad

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

SEC Filings (Institutional Ownership Changes) for Corcept Therapeutics (NASDAQ:CORT)

93.61% of Corcept Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Corcept Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	2,378,758	$110.11M	0.0%	+4.4%	2.270%
11/15/2024	M&T Bank Corp	10,418	$0.48M	0.0%	-4.9%	0.010%
11/15/2024	Executive Wealth Management LLC	60,594	$2.80M	0.2%	N/A	0.058%
11/15/2024	Tanaka Capital Management Inc.	112,136	$5.19M	12.0%	+11.8%	0.107%
11/15/2024	MML Investors Services LLC	6,855	$0.32M	0.0%	N/A	0.007%
11/15/2024	EP Wealth Advisors LLC	6,524	$0.30M	0.0%	N/A	0.006%
11/15/2024	Wellington Management Group LLP	41,066	$1.90M	0.0%	-9.3%	0.039%
11/15/2024	Two Sigma Advisers LP	457,100	$21.16M	0.0%	-11.2%	0.436%
11/15/2024	State Street Corp	3,519,263	$162.87M	0.0%	+0.6%	3.359%
11/15/2024	Stifel Financial Corp	88,967	$4.12M	0.0%	+30.0%	0.085%
11/15/2024	Jacobs Levy Equity Management Inc.	1,223,781	$56.64M	0.2%	+40.5%	1.168%
11/15/2024	Janus Henderson Group PLC	324,017	$15M	0.0%	-5.2%	0.309%
11/15/2024	HighTower Advisors LLC	71,666	$3.31M	0.0%	-7.5%	0.068%
11/14/2024	Verition Fund Management LLC	8,758	$0.41M	0.0%	-76.8%	0.008%
11/14/2024	Captrust Financial Advisors	103,740	$4.80M	0.0%	-15.7%	0.099%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	202,352	$9.37M	0.0%	-8.2%	0.193%
11/14/2024	Public Sector Pension Investment Board	197,295	$9.13M	0.0%	-2.1%	0.188%
11/14/2024	MetLife Investment Management LLC	46,658	$2.16M	0.0%	-0.4%	0.045%
11/13/2024	BNP Paribas Financial Markets	100,088	$4.63M	0.0%	-46.7%	0.096%
11/13/2024	FMR LLC	1,363,922	$63.12M	0.0%	+24.6%	1.302%
11/13/2024	The Manufacturers Life Insurance Company	50,996	$2.36M	0.0%	+4.5%	0.049%
11/13/2024	Hancock Whitney Corp	22,954	$1.06M	0.0%	+1.2%	0.022%
11/12/2024	Alpha DNA Investment Management LLC	10,016	$0.46M	0.2%	N/A	0.010%
11/12/2024	Algert Global LLC	40,115	$1.86M	0.0%	+216.2%	0.038%
11/12/2024	Cerity Partners LLC	611,784	$28.31M	0.1%	-9.4%	0.584%
11/12/2024	Charles Schwab Investment Management Inc.	1,026,487	$47.51M	0.0%	+5.5%	0.980%
11/9/2024	Intech Investment Management LLC	20,532	$0.95M	0.0%	+42.7%	0.020%
11/8/2024	Advisors Asset Management Inc.	12,661	$0.59M	0.0%	+29.7%	0.012%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	859,563	$39.78M	0.2%	+20.0%	0.820%
11/7/2024	Quest Partners LLC	9,256	$0.43M	0.0%	+75.8%	0.009%
11/7/2024	Thrivent Financial for Lutherans	73,030	$3.38M	0.0%	-4.0%	0.070%
11/6/2024	Mutual of America Capital Management LLC	258,753	$11.98M	0.1%	-1.7%	0.247%
11/6/2024	Natixis Advisors LLC	28,144	$1.30M	0.0%	+36.2%	0.027%
11/6/2024	Empowered Funds LLC	38,541	$1.78M	0.0%	N/A	0.037%
11/6/2024	Royce & Associates LP	363,272	$16.81M	0.2%	+3.7%	0.347%
11/6/2024	Black Diamond Financial LLC	5,000	$0.23M	0.0%	N/A	0.005%
11/6/2024	Cornercap Investment Counsel Inc.	9,212	$0.43M	0.1%	-59.9%	0.009%
11/6/2024	CIBC Asset Management Inc	5,214	$0.24M	0.0%	N/A	0.005%
11/6/2024	Intellectus Partners LLC	54,859	$2.54M	0.6%	N/A	0.052%
11/6/2024	Planning Capital Management Corp	1,100	$51K	0.0%	-64.5%	0.001%
11/6/2024	KBC Group NV	2,822	$0.13M	0.0%	+21.3%	0.003%
11/6/2024	Oppenheimer & Co. Inc.	24,774	$1.15M	0.0%	+23.9%	0.024%
11/5/2024	Victory Capital Management Inc.	41,823	$1.94M	0.0%	+49.2%	0.040%
11/4/2024	Versor Investments LP	24,800	$1.15M	0.2%	N/A	0.024%
11/4/2024	Lisanti Capital Growth LLC	113,155	$5.24M	1.3%	+79.6%	0.108%
11/4/2024	State of New Jersey Common Pension Fund D	56,674	$2.62M	0.0%	-3.9%	0.054%
11/4/2024	Meritage Portfolio Management	27,028	$1.25M	0.1%	+10.0%	0.026%
11/1/2024	Assetmark Inc.	63,311	$2.93M	0.0%	+2.0%	0.061%
11/1/2024	CWA Asset Management Group LLC	20,800	$0.96M	0.1%	N/A	0.020%
11/1/2024	Capital Performance Advisors LLP	538	$25K	0.0%	N/A	0.001%
10/31/2024	Principal Financial Group Inc.	495,658	$22.94M	0.0%	-4.0%	0.476%
10/31/2024	M&G PLC	242,901	$11.17M	0.1%	N/A	0.233%
10/30/2024	Amalgamated Bank	27,029	$1.25M	0.0%	-2.2%	0.026%
10/30/2024	QRG Capital Management Inc.	90,202	$4.18M	0.0%	+8.0%	0.087%
10/29/2024	Roman Butler Fullerton & Co.	5,565	$0.26M	0.1%	-65.3%	0.005%
10/29/2024	Robeco Institutional Asset Management B.V.	6,436	$0.30M	0.0%	-66.6%	0.006%
10/28/2024	Oak Ridge Investments LLC	29,080	$1.35M	0.1%	-3.9%	0.028%
10/28/2024	US Bancorp DE	19,683	$0.91M	0.0%	+162.2%	0.019%
10/25/2024	New York State Teachers Retirement System	124,443	$5.76M	0.0%	-12.2%	0.120%
10/25/2024	abrdn plc	666,952	$30.87M	0.1%	+27.1%	0.641%
10/25/2024	Smith Group Asset Management LLC	15,256	$0.71M	0.1%	+25.3%	0.015%
10/24/2024	Nisa Investment Advisors LLC	9,851	$0.46M	0.0%	+83.5%	0.009%
10/24/2024	State of Alaska Department of Revenue	53,045	$2.45M	0.0%	-1.4%	0.051%
10/24/2024	Boston Trust Walden Corp	1,513,975	$70.07M	0.5%	-4.4%	1.454%
10/24/2024	Wealth Enhancement Advisory Services LLC	5,146	$0.24M	0.0%	N/A	0.005%
10/23/2024	Louisiana State Employees Retirement System	45,000	$2.08M	0.0%	-2.4%	0.043%
10/23/2024	Hennion & Walsh Asset Management Inc.	69,327	$3.21M	0.1%	+16.5%	0.067%
10/21/2024	Retirement Guys Formula LLC	5,078	$0.24M	0.1%	N/A	0.005%
10/19/2024	Allspring Global Investments Holdings LLC	251,068	$11.62M	0.0%	+97.2%	0.241%
10/18/2024	AA Financial Advisors LLC	5,000	$0.23M	0.1%	N/A	0.005%
10/18/2024	Blue Trust Inc.	11,658	$0.54M	0.0%	+230.6%	0.011%
10/17/2024	AlphaMark Advisors LLC	9,739	$0.45M	0.2%	+2,269.6%	0.009%
10/16/2024	nVerses Capital LLC	5,600	$0.26M	0.1%	+43.6%	0.005%
10/11/2024	Creative Planning	12,467	$0.58M	0.0%	+7.2%	0.012%
10/11/2024	Kathleen S. Wright Associates Inc.	786	$36K	0.0%	N/A	0.001%
10/10/2024	Exchange Traded Concepts LLC	14,833	$0.69M	0.0%	-80.7%	0.014%
10/8/2024	CWM LLC	8,976	$0.42M	0.0%	+81.5%	0.009%
10/7/2024	GAMMA Investing LLC	2,490	$0.12M	0.0%	+85.4%	0.002%
10/5/2024	Handelsbanken Fonder AB	30,981	$1.43M	0.0%	+60.7%	0.030%
10/3/2024	SG Americas Securities LLC	29,663	$1.37M	0.0%	+262.5%	0.028%
9/5/2024	Sanctuary Advisors LLC	30,466	$0.99M	0.0%	N/A	0.029%
8/27/2024	Clearbridge Investments LLC	570,816	$18.55M	0.0%	-2.0%	0.548%
8/22/2024	Cetera Investment Advisers	38,292	$1.24M	0.0%	+6.2%	0.037%
8/16/2024	Creative Planning	11,626	$0.38M	0.0%	+18.2%	0.011%
8/16/2024	Algert Global LLC	12,685	$0.41M	0.0%	N/A	0.012%
8/15/2024	Mackenzie Financial Corp	6,448	$0.21M	0.0%	-21.9%	0.006%
8/15/2024	The Manufacturers Life Insurance Company	48,780	$1.59M	0.0%	+1.9%	0.047%
8/15/2024	D. E. Shaw & Co. Inc.	949,143	$30.84M	0.0%	-16.2%	0.912%
8/15/2024	AQR Capital Management LLC	239,055	$7.77M	0.0%	-7.5%	0.230%
8/15/2024	AXA S.A.	12,948	$0.42M	0.0%	-42.8%	0.012%
8/14/2024	Marshall Wace LLP	20,200	$0.66M	0.0%	-79.5%	0.019%
8/14/2024	Bank of Montreal Can	12,156	$0.40M	0.0%	+5.0%	0.012%
8/14/2024	Evergreen Capital Management LLC	6,664	$0.22M	0.0%	N/A	0.006%
8/14/2024	Public Sector Pension Investment Board	201,595	$6.55M	0.0%	+8.4%	0.194%
8/14/2024	ProShare Advisors LLC	12,738	$0.41M	0.0%	-23.3%	0.012%
8/14/2024	Profund Advisors LLC	17,321	$0.56M	0.0%	-26.5%	0.017%
8/13/2024	Hancock Whitney Corp	22,684	$0.74M	0.0%	-17.5%	0.022%
8/13/2024	Thrivent Financial for Lutherans	76,057	$2.47M	0.0%	-3.4%	0.073%
8/13/2024	Sei Investments Co.	9,626	$0.31M	0.0%	-84.4%	0.009%
8/13/2024	Public Employees Retirement Association of Colorado	11,693	$0.38M	0.0%	-13.6%	0.011%

Data available starting January 2016

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $54.31

$52.29

$54.57

50 Day Range

MA: $47.21

$35.55

$59.60

52 Week Range

Now: $54.31

$20.84

$61.66

Volume

620,009 shs

Average Volume

1,183,353 shs

Market Capitalization

$5.69 billion

P/E Ratio

43.10

Dividend Yield

N/A

Beta

0.45

Who are the company insiders with the largest holdings of Corcept Therapeutics?: Corcept Therapeutics' top insider investors include:
Sean Maduck (Insider)
Hazel Hunt (Insider)
Gary Charles Robb (Insider)
David L Mahoney (Director)
Joseph Douglas Lyon (Insider)
Joseph Douglas Lyon (CAO)
William Guyer (Insider)
Daniel N Swisher, Jr (Director)
Learn More about top insider investors at Corcept Therapeutics.
Who are the major institutional investors of Corcept Therapeutics?: Corcept Therapeutics' top institutional shareholders include:
State Street Corp — 3.36%
Geode Capital Management LLC — 2.27%
Boston Trust Walden Corp — 1.45%
FMR LLC — 1.30%
Jacobs Levy Equity Management Inc. — 1.17%
Charles Schwab Investment Management Inc. — 0.98%
Learn More about top institutional investors of Corcept Therapeutics stock.
Which institutional investors are selling Corcept Therapeutics stock?: During the last quarter, CORT stock was sold by these institutional investors:
LMR Partners LLP
BNP Paribas Financial Markets
Boston Trust Walden Corp
Cerity Partners LLC
Exchange Traded Concepts LLC
Two Sigma Advisers LP
Verition Fund Management LLC
Principal Financial Group Inc.
During the previous year, company insiders that have sold Corcept Therapeutics company stock include:
Sean Maduck (Insider)
Hazel Hunt (Insider)
Gary Charles Robb (Insider)
David L Mahoney (Director)
Joseph Douglas Lyon (Insider)
Joseph Douglas Lyon (CAO)
Learn More investors selling Corcept Therapeutics stock.
Which institutional investors are buying Corcept Therapeutics stock?: In the previous quarter, CORT stock was bought by institutional investors including:
Jacobs Levy Equity Management Inc.
FMR LLC
M&G PLC
Barclays PLC
Connor Clark & Lunn Investment Management Ltd.
abrdn plc
Allspring Global Investments Holdings LLC
Geode Capital Management LLC